{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:48:54Z","timestamp":1787017734981,"version":"build-2736575974"},"reference-count":32,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T00:00:00Z","timestamp":1657843200000},"content-version":"vor","delay-in-days":195,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003769","name":"Eisai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Parkinson's Disease"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:p>\n                    <jats:italic>Background<\/jats:italic>\n                    . Safinamide is a selective, reversible monoamine oxidase\u2010B inhibitor with a sodium channel inhibitory effect. Published clinical evidence supports safinamide as an effective therapy for Parkinson\u2019s disease (PD) with wearing\u2010off. However, to date, no consensus recommendations have been available to guide physicians in Asia on the optimal use of safinamide in clinical practice. To summarize opinions on the optimal patient profile and methods of using safinamide in common clinical scenarios, Japanese movement disorder specialists with expertise in PD investigated the perspectives of neurologists and neurosurgeons.\n                    <jats:italic>Methods<\/jats:italic>\n                    . The Delphi panel approach was used to summarize the opinions of panelists. The panel comprised doctors from Japan with extensive clinical practice experience in the use of safinamide (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200946 at the final round). The consensus was defined as 80% or more agreement between panelists for each scenario at the final round.\n                    <jats:italic>Results<\/jats:italic>\n                    . There was a high level of agreement that patients with the following symptoms are suitable for safinamide treatment such as bradykinesia (100%), rigidity (95.7%), and\/or gait disorder (89.1%) based on motor symptoms and PD\u2010related pain (97.8%) and\/or depression or apathy (93.5%) based on non\u2010motor symptoms. Morning\u2010off (95.7%), but not dyskinesia (71.7%), also reached consensus. The use of high\u2010dose safinamide (100\u2009mg\/day) was recommended when the improvement in PD symptoms is insufficient and increasing the doses of other anti\u2010PD medications is difficult (97.8%) or when the abovementioned non\u2010motor symptoms adversely affect daily life (93.5%).\n                    <jats:italic>Conclusions<\/jats:italic>\n                    . This report provides expert perspectives on the use of safinamide for a wide range of clinical scenarios in Japan.\n                  <\/jats:p>","DOI":"10.1155\/2022\/3203212","type":"journal-article","created":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T16:50:09Z","timestamp":1657903809000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Collective Expert Perspectives on the Use of Safinamide as Adjunctive Therapy for Parkinson\u2019s Disease: Online\u2010Based Delphi Survey"],"prefix":"10.1155","volume":"2022","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8039-2486","authenticated-orcid":false,"given":"Atsushi","family":"Takeda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6758-0981","authenticated-orcid":false,"given":"Yoshio","family":"Tsuboi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2981-1013","authenticated-orcid":false,"given":"Masahiro","family":"Nomoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0874-7542","authenticated-orcid":false,"given":"Hideki","family":"Mochizuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2034-2556","authenticated-orcid":false,"given":"Nobutaka","family":"Hattori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,7,15]]},"reference":[{"key":"e_1_2_9_1_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.23135"},{"key":"e_1_2_9_2_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.117.245100"},{"key":"e_1_2_9_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3565(24)38068-1"},{"key":"e_1_2_9_4_2","first-page":"1","article-title":"Efficacy and safety evaluation of safinamide as an add-on treatment to levodopa for Parkinson\u2019s disease","volume":"15","author":"Kurihara K.","year":"2021","journal-title":"Expert Opinion on Drug Safety"},{"key":"e_1_2_9_5_2","doi-asserted-by":"publisher","DOI":"10.3233\/jpd-171143"},{"key":"e_1_2_9_6_2","doi-asserted-by":"publisher","DOI":"10.3233\/jpd-160911"},{"key":"e_1_2_9_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2021.118070"},{"key":"e_1_2_9_8_2","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2018.1502165"},{"key":"e_1_2_9_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2015.06.012"},{"key":"e_1_2_9_10_2","doi-asserted-by":"publisher","DOI":"10.3233\/jpd-150700"},{"key":"e_1_2_9_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2021.120083"},{"key":"e_1_2_9_12_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2016.4467"},{"key":"e_1_2_9_13_2","doi-asserted-by":"publisher","DOI":"10.3233\/jpd-202224"},{"key":"e_1_2_9_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.25961"},{"key":"e_1_2_9_15_2","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci11030316"},{"key":"e_1_2_9_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2018.06.033"},{"key":"e_1_2_9_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-021-05607-2"},{"key":"e_1_2_9_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/ene.13567"},{"key":"e_1_2_9_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.1880"},{"key":"e_1_2_9_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2020.04.012"},{"key":"e_1_2_9_21_2","doi-asserted-by":"publisher","DOI":"10.1080\/01616412.2021.1942408"},{"key":"e_1_2_9_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-011-0674-2"},{"key":"e_1_2_9_23_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2012.128"},{"key":"e_1_2_9_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/ene.14552"},{"key":"e_1_2_9_25_2","volume-title":"Japanese Society of Neurolgy","author":"Parkinson\u2019s Disease Practice Guidelines 2018","year":"2018"},{"key":"e_1_2_9_26_2","doi-asserted-by":"publisher","DOI":"10.1097\/wnf.0000000000000233"},{"key":"e_1_2_9_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2020.117012"},{"key":"e_1_2_9_28_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-021-10724-1"},{"key":"e_1_2_9_29_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.22029"},{"key":"e_1_2_9_30_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-010-5817-8"},{"key":"e_1_2_9_31_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-020-02259-y"},{"key":"e_1_2_9_32_2","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci11010057"}],"container-title":["Parkinson's Disease"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/downloads.hindawi.com\/journals\/pd\/2022\/3203212.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/pd\/2022\/3203212.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1155\/2022\/3203212","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T13:43:23Z","timestamp":1757252603000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1155\/2022\/3203212"}},"subtitle":[],"editor":[{"given":"Giuseppina","family":"Martella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["10.1155\/2022\/3203212"],"URL":"https:\/\/doi.org\/10.1155\/2022\/3203212","archive":["Portico"],"relation":{},"ISSN":["2090-8083","2042-0080"],"issn-type":[{"value":"2090-8083","type":"print"},{"value":"2042-0080","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"2022-03-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"3203212"}}